Novel RUNXI-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22)

Genes Chromosomes and Cancer

Volumn 44, Issue 3, 2005, Pages 265-270

  Sakai, Ikuya ^a   Tamura, Tatsushiro ^a   Narumi, Hirosi ^a   Uchida, Naoyuki ^a   Yakushijin, Yoshihiro ^a   Hato, Takaaki ^a   Fujita, Shigeru ^a   Yasukawa, Masaki ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; PROTEIN PRDM16; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ONCOPROTEIN; PRDM16 PROTEIN, HUMAN; RNA; RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CASE REPORT; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 21; FEMALE; GENE FUSION; HUMAN; LEUKEMOGENESIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; RECURRENT DISEASE; TRANSCRIPTION REGULATION; BONE MARROW CELL; CHROMOSOME 1; CHROMOSOME 21; CHROMOSOME BANDING PATTERN; GENE TRANSLOCATION; GENETICS; MALE; METABOLISM; MYELOMONOCYTIC LEUKEMIA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTRAL KARYOTYPING;

AGED; ALTERNATIVE SPLICING; BONE MARROW CELLS; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 21; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SPECTRAL KARYOTYPING; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 25844450207     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20241     Document Type: Article

References (29)

1. Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G. 1993. A region in the C-termimis of adenovirus 2/ 5 E1a protein is required for association with a cellular phosphoprocein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J 12:469-478.
2. Cuenco GM, Nucifora G, Ren R. 2000. Human AML1/MDS1/EVII fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. PrOc Nad Acad Sci USA 97:1760-1765.
3. Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, Nagase T, Yokoyama Y, Ohki M. 1998. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 91:4028-4037.
4. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. 1998. Aberrant recruicment of the nuclear receptor corepressorhistone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185-7191.
5. Hromas R, Busse T, Carroll A, Mack D, Shopnick R, Zang DE, Nakshatri H, Richkind K. 2000a. Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 prorein. Blood 97:2168-2170.
6. Hromas R, Shopnick R, Jumean HG, Bowers C, Varella-Garcia M, Richkind K. 2000b. A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations. Blood 95:4011-4013.
7. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. 2001. The corepressor CtBP interacts with EVI-1 to repress transforming growth factor β signaling. Blood 97:2815-2822.
8. Izutsu K, Kurokawa M, Imai Y, Ichikawa M, Asai T, Maki K, Mitani K, Hirai H. 2002. The t(3;21) fusion product, AML1/EVI-1 blocks AML1-induced transactivation by recruiting CtBP. Oncogene 21:2695-2703.
9. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. 1998. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 17:2994-3004.
10. Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. 1998a. The t(3;21) fusion product, AML1/Evil, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells. Blood 92:478-482.
11. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Mastumoto K, Hirai H. 1998b. The oncoprotein Evi-1 repress TGF-β signaling by inhibiting Smad3. Nature 394:92-96.
12. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, Moriguchi T, Nishida E, Yazaki Y, Hirai H. 2000. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 19:2958-2968.
13. Mikhail E, Coignet L, Hatem N, Mourad ZI, Farawela HM, Kaffash DMEI, Fahla N, Nucifora G. 2004. A novel gene, FGA7. is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 39:110-118.
14. Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H. 1994. Generation of the AML1-EVI-1 fusion gene in the t(3:21)(q26;q22) causes blastic crisis in chronic myelocycic leukemia. EMBO J 13:504-510.
15. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. 1991. t(8;21) Breakpoints in chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 88:10431-10434.
16. Mochizuki N, Shimizu S, Nagasawa T, Tanaka H, Taniwaki M, Yokota J, Morishita K. 2000. A novel gene. MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1:3)(p36;q21)- positive leukemia cells. Blood 96:3209-3214.
17. Nishikata I, Sasaki H, Iga M, Taneo Y, Imayoshi S, Asou N, Nakamura T, Morishita K. 2003. A novel EVI1 gene family, MEL1, lacking a PR domain (MELlS) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. Blood 102:3323-3332.
18. Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowley JD. 1993a. The 3:21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER-1. Proc .Natl Acad Sci USA 90:7784-7788.
19. Nucifora G, Birn D, Espinosa R, Erickson P, Le Beau MM, Roulston D, McKeithan TW, Drabkin H, Rowley JD. 1993b. Involvement of AML1 gene in t(3:21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 81:2728-2734.
20. Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D. Pedersen-Bjergaard J, Parganas E, Ihle JN. 1994. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci USA 92:4004-4008.
21. Roulston D, Espinosa R, III, Nucifora G, Larson RA, Le Beau MM, Rowley DR. 1998. CBFA2(AML1) translocation with novel partner chromosome in myeloid leukemia: association with prior therapy. Blood 92:2879-2885.
22. Sato Y, Izumi T, Kanamori H, Davis EM, Miura Y, Larson RA, Le Beau MM, Ozawa K, Rowley JD. 2002. t(1;3)(p36;q21) is a recurring therapy-related translocation. Gene Chromosomes Cancer 34:186-192.
23. Seeker-Walker LM, Mehta A, Bain B. 1995. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom cancer cytogenetic group study. Br J Haematol 91:490-501.
24. Senyuk V, Chakrabory S, Mikhail FM, Zhao R, Chi Y, Nucifora G. 2002. The leukemia-associated transcription repressor AML1/MDS1/EVI1 require CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene 21:3232-3240.
25. Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, Hirai H. 1994. Evi-1 raises Ap-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 269:24020-24026.
26. Tighe JE, Calabi E. 1994. Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2. Blood 84:2115-2121.
27. Webb DK, Passmore SJ, Hann IM, Harrison G, Wheatley K, Chesslls JM. 2002. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. Br J Haematol 117:33-39.
28. Zang Y, Emmanuel N, Kamboji G, Chen J, Shurafa M, Van Dyke DL, Wiktor A, Rowley JD. 2004. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22). Genes Chromosomes Cancer 40:365-370.
29. Zent CS, Mathieu C, Claxton DF, Zhang DE, Tenen DG, Rowley JD, Nucifora G. 1996. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties. Proc Natl Acad Sci USA 93:1044-1048.